Hepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM).
Hepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM).
复制标题
功能性磁共振成像（HEPARIM）肝切除术风险评估。
DOI：
10.1186/s12885-021-08830-4
复制
发表时间：
2021-10-23
期刊：
影响因子：
3.8
通讯作者：
Sourbron S
中科院分区：
文献类型：
--
作者：
Elsharif M;Roche M;Wilson D;Basak S;Rowe I;Vijayanand D;Feltbower R;Treanor D;Roberts L;Guthrie A;Prasad R;Gilthorpe MS;Attia M;Sourbron S
肝切除术后肝衰竭（PHLF）仍然是接受根治性肝切除术治疗癌症的患者的一个重大风险，但目前可用的PHLF风险预测研究不够准确。肝切除术风险评估与功能性磁共振成像试验（HEPARIM）旨在确定肝功能和灌注的定量MRI生物标志物是否可用于更准确地预测PHLF风险和FLR功能，根据吲哚菁绿色（ICG）肝功能试验进行测量。HEPARIM是一项观察性队列研究，招募了接受2个或更多肝段切除术的患者，手术前患者将接受动态甘氨酯增强（DGE）肝脏MRI和ICG检测。重复术后第一天的ICG测试，并将R15与通过术前DGE-MRI测量的未来肝脏残留物的甘胆酸盐清除率（GC）（FLR-GC）进行比较，这是主要结果，并将术前ICG R15与全肝GC（WL-GC）进行比较，作为次要结果。将从医疗记录、生化、病理学和放射学报告中收集数据，并将其用于功能性MRI价值的多变量分析，并推导出多变量预测模型以供将来验证。如果成功，该测试将可能提供一种有效的手段来定量评估FLR功能和PHLF风险，使外科医生能够进一步推动肝脏手术的界限，同时保持安全实践，从而为以前被认为不可手术的患者提供治愈的机会。MRI具有额外的好处，因为它已经成为常规诊断途径的一部分，因此对患者的时间或医疗保健系统的成本造成的额外负担有限。（功能性磁共振成像的肝切除术风险评估-全文查看-ClinicalTrials.gov，n.d.）ClinicalTrials.gov，ClinicalTrials.gov NCT 04705194-注册日期：2021年1月12日-Retrospective注册在线版本包含补充材料，可通过10.1186/s12885-021-08830-4获得。
Post hepatectomy liver failure (PHLF) remains a significant risk in patients undergoing curative liver resection for cancer, however currently available PHLF risk prediction investigations are not sufficiently accurate. The Hepatectomy risk assessment with functional magnetic resonance imaging trial (HEPARIM) aims to establish if quantitative MRI biomarkers of liver function & perfusion can be used to more accurately predict PHLF risk and FLR function, measured against indocyanine green (ICG) liver function test. HEPARIM is an observational cohort study recruiting patients undergoing liver resection of 2 segments or more, prior to surgery patients will have both Dynamic Gadoxetate-enhanced (DGE) liver MRI and ICG testing. Day one post op ICG testing is repeated and R15 compared to the Gadoxetate Clearance (GC) of the future liver remnant (FLR-GC) as measure by preoperative DGE- MRI which is the primary outcome, and preoperative ICG R15 compared to GC of whole liver (WL-GC) as a secondary outcome. Data will be collected from medical records, biochemistry, pathology and radiology reports and used in a multi-variate analysis to the value of functional MRI and derive multivariant prediction models for future validation. If successful, this test will potentially provide an efficient means to quantitatively assess FLR function and PHLF risk enabling surgeons to push boundaries of liver surgery further while maintaining safe practice and thereby offering chance of cure to patients who would previously been deemed inoperable. MRI has the added benefit of already being part of the routine diagnostic pathway and as such would have limited additional burden on patients time or cost to health care systems. (Hepatectomy Risk Assessment With Functional Magnetic Resonance Imaging - Full Text View - ClinicalTrials.gov, n.d.) ClinicalTrials.gov, ClinicalTrials.gov NCT04705194 - Registered 12th January 2021 – Retrospectively registered The online version contains supplementary material available at 10.1186/s12885-021-08830-4.
登录
查看更多内容
影响因子：
2.9
作者：
Bluethner, Elisabeth;Jara, Maximilian;Malinowski, Maciej
通讯作者：
Malinowski, Maciej
影响因子：
3.8
作者：
Cieslak, Kasia P.;Huisman, Floor;van Gulik, Thomas M.
通讯作者：
van Gulik, Thomas M.
影响因子：
9
作者：
Paugam-Burtz, Catherine;Janny, Sylvie;Belghiti, Jacques
通讯作者：
Belghiti, Jacques
DOI：
10.1002/lt.20041
发表时间：
2004-02-01
期刊：
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
影响因子：
--
作者：
Jaeck, Daniel;Bachellier, Philippe;Wolf, Philippe
通讯作者：
Wolf, Philippe
影响因子：
19.7
作者：
Sourbron, Steven;Sommer, Wieland H.;Zech, Christoph J.
通讯作者：
Zech, Christoph J.